A detailed history of Janus Henderson Group PLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 32,000 shares of ALT stock, worth $303,680. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,000
Holding current value
$303,680
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.91 - $10.23 $189,120 - $327,360
32,000 New
32,000 $212,000
Q1 2023

May 15, 2023

SELL
$4.19 - $16.83 $16 Million - $64.1 Million
-3,809,593 Reduced 99.37%
23,986 $101,000
Q4 2022

Feb 14, 2023

SELL
$8.74 - $16.45 $2.52 Million - $4.74 Million
-288,235 Reduced 6.99%
3,833,579 $63.1 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $44 Million - $92.4 Million
4,121,814 New
4,121,814 $52.6 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $465M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.